Friedel, Evelyn B. N. http://orcid.org/0000-0001-9862-9656
Haldina, Julia http://orcid.org/0009-0004-1999-8859
Nickel, Kathrin http://orcid.org/0000-0001-9863-317X
Bach, Michael http://orcid.org/0000-0003-2028-535X
Tebartz van Elst, Ludger http://orcid.org/0000-0002-2274-5447
Heinrich, Sven P. http://orcid.org/0000-0003-4906-3937
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (462923710)
Universitätsklinikum Freiburg
Article History
Received: 5 October 2023
Accepted: 20 January 2024
First Online: 28 February 2024
Declarations
:
: Evelyn B. N. Friedel has no conflict of interest; Julia Haldina has no conflict of interest; Ludger Tebartz van Elst involved in advisory boards, lectures, or travel grants within the last three years: Roche, Eli Lilly, Janssen-Cilag, Novartis, Shire, UCB, GSK, Servier, Janssen and Cyberonics, and Kathrin Nickel have no conflict of interest; Michael Bach has no conflict of interest; Sven P. Heinrich has no conflict of interest.
: The study protocol was approved by the local Ethics Committee of the University of Freiburg (Approval ID: 314/18).
: All participants provided written informed consent to participate in the study.
: All procedures performed in the scope of the study were in agreement with the local ethical standards, as well as in accordance with the tenets of the Declaration of Helsinki.
: No animal experiments were conducted for the study.